Oncotarget

Research Papers:

Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma

Roberto Carmagnani Pestana, Manal M. Hassan, Reham Abdel-Wahab, Yehia I. Abugabal, Lauren M. Girard, Donghui Li, Ping Chang, Kanwal Raghav, Jeff Morris, Robert A. Wolff, Asif Rashid, Hesham M. Amin and Ahmed Kaseb _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:37721-37732. https://doi.org/10.18632/oncotarget.26507

Metrics: PDF 546 views  |   HTML 1381 views  |   ?  


Abstract

Roberto Carmagnani Pestana1, Manal M. Hassan2, Reham Abdel-Wahab3,7, Yehia I. Abugabal3, Lauren M. Girard3, Donghui Li3, Ping Chang3, Kanwal Raghav3, Jeff Morris4, Robert A. Wolff3, Asif Rashid5, Hesham M. Amin6 and Ahmed Kaseb3

1Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

4Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

5Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

6Department of Hemopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

7Department of Clinical Oncology, Assiut University Hospitals, Faculty of Medicine, Assiut, Egypt

Correspondence to:

Ahmed Kaseb, email: aokaseb@mdanderson.org

Manal M. Hassan, email: mhassan@mdanderson.org

Keywords: angiogenesis; angiopoietin-1; angiopoietin-2; cirrhosis; hepatocellular carcinoma

Abbreviations: Ang-1: angiopoietin-1; Ang-2: angiopoietin-2; HCC: hepatocellular carcinoma; mAB: monoclonal antibody; OS: overall survival

Received: August 08, 2018     Accepted: November 16, 2018     Published: December 28, 2018

ABSTRACT

Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) play critical roles in angiogenesis in hepatocellular carcinoma (HCC). In addition, recent data suggest that Ang-1/Ang-2 are involved in regulating the immune response. The aim of our study was to explore the clinical prognostic significance of plasma Ang-1 and Ang-2 in HCC. We prospectively enrolled and collected data and blood samples from 767 HCC patients treated at MD Anderson Cancer Center between 2001 and 2014. Controls consisted of cirrhotic patients (n = 75) and healthy volunteers (n = 200). The cutoff value was the median level of each angiogenic factor. Overall survival (OS) was estimated by Kaplan–Meier curves and compared by the log-rank test. Higher plasma Ang-2 was significantly associated with advanced clinicopathologic features of advanced HCC and lower OS. Median OS was 61.8 months (95% confidence interval [CI], 45.1–78.5 months) for low Ang-2 compared with 28.5 months (95% CI, 24.8–32.1 months) for high Ang-2 (p < 0.001). In contrast, higher Ang-1 was associated with longer OS. Median OS was 37.2 months (95% CI, 31.0–43.4 months) for high Ang-1 compared with 26.2 months (95% CI, 22.2–30.3 months) for those with low Ang-1 (p = 0.043). In conclusion, our findings indicate that plasma Ang-1 and Ang-2 levels are potential diagnostic and prognostic biomarkers in HCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26507